Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Ju Fu Tang Biotech Holdings Co's annualized net income for the quarter that ended in Sep. 2025 was HK$42.88 Mil. Ju Fu Tang Biotech Holdings Co's average shareholder tangible equity for the quarter that ended in Sep. 2025 was HK$37.94 Mil. Therefore, Ju Fu Tang Biotech Holdings Co's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was 113.02%.
The historical rank and industry rank for Ju Fu Tang Biotech Holdings Co's Return-on-Tangible-Equity or its related term are showing as below:
HKSE:08217'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -97.76 Med: -18.75 Max: 59.98
Current: 55.34
During the past 13 years, Ju Fu Tang Biotech Holdings Co's highest Return-on-Tangible-Equity was 59.98%. The lowest was -97.76%. And the median was -18.75%.
HKSE:08217's Return-on-Tangible-Equity is ranked better than 90.25% of 1713
companies
in the Construction industry
Industry Median: 8.19
vs HKSE:08217: 55.34
Ju Fu Tang Biotech Holdings Co (HKSE:08217) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Ju Fu Tang Biotech Holdings Co Return-on-Tangible-Equity Related Terms
Ju Fu Tang Biotech Holdings Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ju Fu Tang Biotech Holdings Co Return-on-Tangible-Equity Chart
HKSE:08217 vs PWR, FIX, EME: Return-on-Tangible-Equity Comparison
For the Engineering & Construction subindustry, Ju Fu Tang Biotech Holdings Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ju Fu Tang Biotech Holdings Co Return-on-Tangible-Equity vs Construction Industry
For the Construction industry and Industrials sector, Ju Fu Tang Biotech Holdings Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Ju Fu Tang Biotech Holdings Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Sep. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 113.02% mean?
Ju Fu Tang Biotech Holdings Co (HKSE:08217) has a Return-on-Tangible-Equity of 113.02% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ju Fu Tang Biotech Holdings Co and its competitors. According to the industry distribution chart, Ju Fu Tang Biotech Holdings Co ranks #167 out of 1713 companies in the Construction industry, placing it in the top 9.7%.
Is Ju Fu Tang Biotech Holdings Co's Return-on-Tangible-Equity too high?
Ju Fu Tang Biotech Holdings Co's current Return-on-Tangible-Equity is 113.02%. The Construction industry median Return-on-Tangible-Equity is 8.19. Ju Fu Tang Biotech Holdings Co's value of 113.02% is 1280% above this industry median. Based on the distribution chart, Ju Fu Tang Biotech Holdings Co ranks #167 out of 1713 companies in the Construction industry, which is in the top quartile — a strong position relative to peers. Overall, Ju Fu Tang Biotech Holdings Co has a GF Score™ of 36/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ju Fu Tang Biotech Holdings Co's Return-on-Tangible-Equity compare to PWR and FIX?
According to the Construction industry distribution chart, Ju Fu Tang Biotech Holdings Co ranks #167 out of 1713 companies for Return-on-Tangible-Equity. This places Ju Fu Tang Biotech Holdings Co in the top 10% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Equity is 8.19. Ju Fu Tang Biotech Holdings Co's value of 113.02% is 1280% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Construction company?
The median Return-on-Tangible-Equity among Construction companies is 8.19, based on 1,713 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ju Fu Tang Biotech Holdings Co's current Return-on-Tangible-Equity of 113.02% is 1280% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Ju Fu Tang Biotech Holdings Co and its competitors. For the Construction industry, the median Return-on-Tangible-Equity is 8.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ju Fu Tang Biotech Holdings Co's current Return-on-Tangible-Equity is 113.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ju Fu Tang Biotech Holdings Co stock overvalued right now?
Based on GuruFocus' analysis, Ju Fu Tang Biotech Holdings Co (HKSE:08217) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$0.15, compared to a current price of HK$0.11 — trading 26% below its estimated fair value. The current Return-on-Tangible-Equity is 113.02% and 1280% above the Construction industry median of 8.19. Ju Fu Tang Biotech Holdings Co's overall GF Score™ is 36/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Ju Fu Tang Biotech Holdings Co (HKSE:08217), the current Return-on-Tangible-Equity is 113.02% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ju Fu Tang Biotech Holdings Co (HKSE:08217) Overvalued in 2026?
Based on GuruFocus' analysis, Ju Fu Tang Biotech Holdings Co stock appears to be undervalued.
The current stock price of HK$0.11 is trading 26% below its estimated GF Value™ of HK$0.15.
GuruFocus considers Ju Fu Tang Biotech Holdings Co to be Modestly Undervalued.
Key valuation signals for HKSE:08217:
Return-on-Tangible-Equity: 113.02%
GF Value™: HK$0.15 vs. price of HK$0.11 (26% below fair value)
Industry Position: 1280% above the Construction median (#167 of 1713)
No single metric tells the full story. See the HKSE:08217 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ju Fu Tang Biotech Holdings Co Ltd, formerly known as WMHW Holdings Ltd, is an investment holding company operating through its subsidiaries. It engaged in the provision of construction works and investment holding.
36GF Score
Get the complete analysis for HKSE:08217
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08217 has been successfully added to your 
